Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00409942
Status:
COMPLETED
Last Update Posted:
2009-07-15
First Post:
2006-12-11
Brief Title:
Effect of a New Formulation of Torasemide Prolonged Releaseon Myocardial Fibrosis in Patients With Heart Failure
Sponsor:
Ferrer Internacional SA
Organization:
Ferrer Internacional SA
Study Overview
Official Title:
Prospective Randomised Open Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TORAFIC
Brief Summary:
Torasemide is a loop diuretic pyridine-sulfonylureawith a wide experience in the treatment of oedema associated to heart failure kidney or liver disease and either in the treatment of arterial hypertension alone or combined with other anti-hypertensive drugs It has been developed a new formulation of Torasemide Torasemide prolonged release
The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide in the reduction of myocardial fibrosis in patients with chronic heart failure Class II-IV of the New York Heart Association Classification
The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide in the reduction of myocardial fibrosis in patients with chronic heart failure Class II-IV of the New York Heart Association Classification
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT number 2006-001446-14 | None | None | None |